9, 2008, to Jan. 21, 2015. Patients were eligible for the study if they had stable or unstable angina pectoris or non-ST-elevation myocardial infarction (MI). ... The primary outcome was a composite of death and thrombotic events (nonfatal myocardial
A new score may help predict outcomes for patients who were successfully resuscitated after out-of-hospital cardiac arrest for reasons other than ST-elevation myocardial infarction (STEMI).
additional intervention, thrombosis, and myocardial infarction.
The ivabradine patients also had 11% lower risk of cardiovascular death or nonfatal myocardial infarction, according to results presented at the American College of Cardiology's annual meeting this year.
The primary outcome was 30-day mortality, and secondary outcomes were a composite of mortality or other medical complications (myocardial infarction, deep vein thrombosis, pulmonary embolism, and pneumonia).
Patients with heart failure and myocardial infarction are at an increased risk of developing atrial fibrillation. ... Flecainide is contraindicated after a myocardial infarction because it increases the risk of polymorphic ventricular tachycardia.
Cardiomyopathy, literally “a disease of the heart,” includes a large variety of myocardial disorders involving structural and functional abnormalities. ... In summary, cardiomyopathy encompasses a large variety of myocardial disorders involving
The primary outcome measure was death, myocardial infarction, or stroke at 30 days after surgery. ... Researchers also evaluated individual index hospitalizations for heart failure, myocardial infarction, and pneumonia.
The study excluded 28% of patients with isolated CABG because of a myocardial infarction within 21 days before surgery, thus eliminating patients with ST-elevation myocardial infarction (STEMI) and non-STEMI;.
A consensus document from several cardiology organizations recently provided new official definitions of myocardial infarction (MI). ... Prior myocardial infarction is defined by any one of the following:.